In a recent noteworthy development, Celgene Corporation and its parent company Bristol-Myers Squibb have cited another antitrust case dismissal, an occurrence that has implications in their endeavours to evade antitrust allegations related to cancer medicines.
The cited case revolved around AbbVie Inc.’s hypertension drug named Bystolic. This case of alleged restriction of the generic competition was eventually dismissed and the decision upheld by the Second Circuit. Believing that a similar logic could be applied to their circumstances, Bristol-Myers Squibb has drawn the attention of a New Jersey federal judge to this dismissal as an argument in their ongoing legal battle.
It is noteworthy that the legal landscape is complex, and this case is yet another instance of how companies strive to navigate it while dealing with intense competition and regulatory scrutiny.
For more detailed information, you can read the full story at Law360.